证券代码：300294 证券简称：博雅生物 公告编号：2025-060 华润博雅生物制药集团股份有限公司 关于使用银行承兑汇票支付募集资金投资项目资金 并以募集资金等额置换的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司、博雅生物）于2019 年4月15日召开第六届董事会第二十三次会议、第六届监事会第二十次会议，会 议审议通过了《关于使用银行承兑汇票支付募投项目所需资金并以募集资金等额 置换的议案》，同意公司在募集资金投资项目（以下简称募投项目）实施期间， 根据实际情况使用银行承兑汇票支付募投项目中的应付工程款、设备采购款、材 料采购款等款项，并从募集资金账户划转等额资金至公司自有资金账户。具体内 容详见公司于2019年4月15日在巨潮资讯网上披露的《关于使用银行承兑汇票支 付募投项目所需资金并以募集资金等额置换的公告》。 | 加：本年度募集资金理财产品收益、利息收入减除手续费净额 | 13,315,616.97 | | --- | --- | | 二、使用配套募集资金 | 1,085,783,062.77 | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shenzhou Cell, which has a high PE ratio compared to its industry peers [1][2] - As of August 19, Shenzhou Cell's stock closed at 71.4 yuan, down 2.19%, with a rolling PE ratio of 313.20 and a total market capitalization of 31.797 billion yuan [1] - The average PE ratio for the biopharmaceutical industry is 73.41, with a median of 45.28, placing Shenzhou Cell at the 72nd position among its peers [1][2] Group 2 - As of the first quarter of 2025, 17 institutions hold shares in Shenzhou Cell, with a total of 2.7733 million shares valued at 166 million yuan [1] - The company specializes in the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune diseases, with key products such as SCT800 and SCT400 [1] - In the latest financial report for the first quarter of 2025, Shenzhou Cell reported a revenue of 520 million yuan, a year-on-year decrease of 15.15%, and a net profit of 63.768 million yuan, down 14.06%, with a gross margin of 94.88% [1]

Core Viewpoint - The company plans to divest 80% of its stake in Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. to focus on its core blood products business and optimize resource allocation, enhancing capital return levels [1][3]. Group 1: Transaction Details - The transaction will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with an initial listing price of 213 million yuan, subject to the valuation approved by the state-owned assets supervision authority [1]. - After the completion of the share transfer, the company will hold 10.69% of Boya Xinhao, and it will no longer be included in the company's consolidated financial statements [2]. Group 2: Business Performance - In 2024, the company reported total revenue of 1.735 billion yuan, a decrease of 34.58% year-on-year, while net profit attributable to shareholders was 397 million yuan, an increase of 67.18% compared to the previous year [2]. - The company achieved a plasma collection of 630.6 tons in 2024, representing a year-on-year growth of 10.4%, with the main entity, China Resources Boya, collecting 522.04 tons, up 11.7%, exceeding the industry average growth rate [2]. Group 3: Strategic Implications - The divestiture is expected to optimize the company's business structure, focus on core development, enhance sustainable internal growth, facilitate capital flow, and activate existing production capacity, ultimately promoting high-quality development [3].

Market Overview - The Shanghai Composite Index closed at 3653.50 points, with a change of +0.51% [1] - The total trading volume of A-shares reached 1,149.623 billion yuan [1] Technical Analysis - A total of 17 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Angli (002940) with a distance of -1.91% - Chengdu Xian Dao (688222) with a distance of -1.51% - Saiseng Pharmaceutical (300485) with a distance of -1.38% [1] Individual Stock Performance - Angli (002940) saw a daily increase of 2.02% with a turnover rate of 4.48% [1] - Chengdu Xian Dao (688222) increased by 1.47% with a turnover rate of 2.10% [1] - Saiseng Pharmaceutical (300485) experienced a slight decrease of -0.14% with a turnover rate of 3.10% [1] - Other stocks with notable performance include: - Jintai (688443) up by 1.78% - Changshan Pharmaceutical (300255) up by 2.29% - Zhizheng (603991) down by -1.69% [1]

Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002773 | 康弘药业 | 42.26 | -7.00% | 14.13万 | 6.15亿 | | 688520 | 神州细胞 | 66.60 | -4.57% | 7.24万 | 4.90 Z | | 688293 | 奧浦迈 | 55.27 | -4.06% | 1.63万 | 9079.15万 | | 688331 | 荣昌生物 | 61.81 | -4.02% | 6.31万 | 3.95/Z | | 688336 | 三生国健 | 49.70 | -3.78% | 6.60万 | 3.31 Z | | 688180 | 君实生物 | 39.85 | -3.46% | 25.62万 | 10.28亿 | | 000534 | 万泽股份 | 15.68 | -2.97% | 40.11万 | 6.38亿 | | 603087 | 日李药业 | 62.46 | -2.95% | 19.26万 | 12.12亿 | | 688177 | 百奧 ...

（文章来源：证券日报） 证券日报网讯博雅生物8月6日在互动平台回答投资者提问时表示，公司2025年7月31日含信用账户合并 名册的股东人数为29，062户。 ...

Core Viewpoint - The control transfer of blood product company Palin Bio (000403.SZ) has encountered complications, primarily due to competition concerns with Tian Tan Bio (600161.SH), which is also controlled by China Biotech [1][6]. Group 1: Acquisition Plans - In June, China Biotech planned to acquire 21.03% of Palin Bio from its controlling shareholder, Shengbang Yinghao Investment Partnership, for no less than 3.844 billion yuan [1]. - Tian Tan Bio rejected the acquisition opportunity, citing a short three-month window to raise the necessary funds, with a cash balance of only 2.686 billion yuan as of the end of 2024 [2]. - Tian Tan Bio expressed concerns over the complex history of Palin Bio's control and the associated risks of a direct acquisition [3]. Group 2: Board Changes and Management Conflicts - In October 2023, Palin Bio's board was re-elected, with Shengbang Yinghao nominating 13 directors and ousting the former chairman, Fu Shaolan [4]. - Fu Shaolan retaliated by advocating for a more balanced governance structure and warning against the consequences of unethical behavior, leading to a temporary resolution where he was appointed as co-chairman alongside the new chairman [5]. Group 3: Strategic Considerations - Tian Tan Bio's reluctance to acquire Palin Bio directly stems from a desire for a more strategic approach, suggesting that China Biotech should first acquire Palin Bio to facilitate smoother integration and operational efficiency [6][7]. - If the acquisition is successful, the combined entities would control at least 123 plasma collection stations, with a total collection volume of 4,181 tons, significantly enhancing their market position [8][9]. - The combined market share of Tian Tan Bio and Palin Bio could approach 30%, increasing by over 10 percentage points, thereby solidifying their leadership in the industry [9].

Market Overview - The Shanghai Composite Index closed at 3568.96 points, above the six-month moving average, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,180.388 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 99 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Mengsheng Electronics: 5.86% - Guanghong Technology: 4.32% - Jinyang Co., Ltd.: 3.70% [1] Detailed Stock Performance - Top performers on August 4th with deviation rates: - Mengsheng Electronics (688311): Today's change of 7.40%, turnover rate of 4.63%, six-month line at 37.68 yuan, latest price at 39.89 yuan [1] - Guanghong Technology (300735): Today's change of 6.10%, turnover rate of 4.73%, six-month line at 27.36 yuan, latest price at 28.54 yuan [1] - Jinyang Co., Ltd. (301210): Today's change of 5.60%, turnover rate of 15.69%, six-month line at 42.39 yuan, latest price at 43.96 yuan [1] Additional Notable Stocks - Other stocks with positive performance and deviation rates include: - Zhenjiang Co., Ltd. (603507): 5.00% change, 12.19% turnover, six-month line at 24.79 yuan, latest price at 25.60 yuan [1] - Baiao Chemical (603360): 5.59% change, 2.66% turnover, six-month line at 20.51 yuan, latest price at 21.16 yuan [1] - Stocks with smaller deviation rates that just crossed the six-month line include: - Deep Technology (300735): 6.10% change, 4.73% turnover, six-month line at 27.36 yuan, latest price at 28.54 yuan [1] - Qiming Information (301210): 5.60% change, 15.69% turnover, six-month line at 42.39 yuan, latest price at 43.96 yuan [1]

人民财讯8月4日电，生物制品板块拉升，天坛生物涨停，万泽股份此前封板，艾迪药业、智飞生物、博 雅生物、博晖创新、派林生物等跟涨。 （原标题：生物制品板块拉升 天坛生物涨停） ...